ClinicalTrials.gg
RecruitingNCT05361980Global POISEUpdated Nov 9, 2026

Pediatric Orthopaedic Implant Safety & Efficacy

An observational study in Fracture, Lengthening; Leg and Orthopedic Disorder, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 0 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of British Columbia · Observational

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
0 Years to 25 Years
Sex
All
01

Study summary

Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity.

Given the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy.

Prospective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).

Read the detailed description

STUDY PROCEDURES Screening Patients will be screened against basic inclusion/exclusion criteria to see if patients may be appropriate for study participation according to any standard of care assessments available, and where appropriate with the site's REB/IRB screening procedures and local regulatory requirements. If a patient is deemed eligible, data outlined throughout this protocol will be collected, de-identified and entered into a Research Electronic Database Capture (REDCap) system managed at BCCH.

Enrollment Patients will be assigned a sequential, unique study number (subject ID) and de-identified data will be entered in the study database. The center number is designated by the BCCH team for each individual investigational site. The patient number will be in sequential order by the patient screening date starting with 001. Once a patient has been assigned a subject ID, the number will not be reused.

Pre-Operative Procedures Once a patient is identified as eligible for an Implant Safety and Efficacy device report, it will be determined whether that patient is already enrolled in one of the existing condition-specific registries. Should participants be enrolled in a condition-specific registry, demographic data, medical history, preoperative clinical data, including any pre-existing infections at or near the operative site, and data on pre-operative radiographs for the relevant underlying diagnosis will have already been prospectively collected under registry procedures. If a patient has not been previously enrolled in a condition-specific registry, the patient will be offered enrollment in both the condition registry and for the purposes of the Implant Safety and Efficacy device report. Demographic data, medical history, preoperative clinical data and data on pre-operative radiographs for the relevant underlying diagnosis will then be collected retrospectively from the medical record.

Required Data Collection:

Operative details in the source documentation will be collected that provide specific information from the subject's surgery such as surgical approach, complications, and unique device identification (UDI) numbers for the implanted device.

The following data will be collected and entered into the registry:

  • Operative data, specific to the technique related to the relevant OrthoPediatrics system/device
  • Assessments of any device-related adverse events
  • Assessment for other adverse events
  • When possible, the UDI number for the device(s) implanted, or information on the device implanted

Follow-up Procedures

Data collected during routine standard of care follow-up visits will be collected as part of this study. The following data will be collected:

  • Radiographs obtained during study clinical evaluations to determine bony union, as well as healing or complications
  • Device-related adverse events
  • Unanticipated device-related serious adverse device effects
  • Information on implant removals not related to an adverse event; degree of bony union just prior to implant removal Unscheduled Visits [if or when needed]

The condition-specific registries are designed to capture every visit that occurs, whether scheduled or unscheduled. An unscheduled visit may occur when an adverse event occurs, or when a patient returns outside of the planned interval window. If an unscheduled visit occurs, the following assessments are to be done:

  • Assessment of any adverse events related to the device
  • Survivorship of the device
02

Conditions studied

  • Fracture
  • Lengthening; Leg
  • Orthopedic Disorder
  • Deformity of Limb
  • Deformity; Bone
  • Implant Breakage
  • Implant Complication
  • Hip Dysplasia
  • Pediatric ALL
  • Hip Disease
  • Hip Dislocation
03

In context

Fractures, Bone

723 studies on the registry are indexed under Fractures, Bone; 114 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 130 across 239 observational studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Anyone who meets the eligibility criteria and is within the age limits listed in the above sections can participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. Off-label use is strongly discouraged; however, any and all on- and off-label indications for use of the products in this program will be collected and stratified accordingly
  • Patients must be able to adhere to the required length of follow-up for the endpoints of each individual product
  • /assent is required

Exclusion criteria

Exclusion Criteria:

  • Patients with a demonstrated sensitivity to metals
  • Patients with an inability to follow a post-operative regimen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Longitudinal Observational Group

    Pediatric patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU.

    Device: Pediatric orthopaedic implant

Interventions

  • DevicePediatric orthopaedic implant

    Patient receives a pediatric orthopaedic implant as a part of standard clinical care.

06

What researchers measure

Primary outcomes

  1. Device related adverse events

    Determine the frequency and severity of device-related adverse events at device-specific end points. All adverse events will be recorded and followed during the study. The frequency and severity of device related adverse events will be analyzed to ensure the device risk profile has not changed.

    Time frame: 2 years post implant insertion

  2. Implant survival

    Determine the implant survival rate at post-operative end-point: (lack of revision)

    Time frame: 2 years post implant insertion

  3. Implant efficacy

    Efficacy will be assessed by post-operative clinical and radiographic evaluations at each follow-up end-point to assess bone fixation and/or deformity correction.

    Time frame: 2 years post implant insertion

Secondary outcomes

  1. Numeric pain rating scale (NPRS)

    The numeric pain rating scale (NPRS) is a subjective, 11-point numerical scale in which respondents self-report their pain on a scale of 0 (no pain at all) to 10 (worst pain imaginable).

    Time frame: 2 years post implant insertion

  2. LIMB-Q Kids

    LIMB-Q Kids is a new patient reported outcome measure (PROM) for children with lower limb deformities.

    Time frame: 2 years post implant insertion

  3. PROMIS

    The Patient Reported Outcomes Measurement Information System (PROMIS) measures are self-reported and parent-reported. It includes over 300 measures of global, physical, mental, and social health for adults and children in the general population and those living with a chronic condition. Specifically, the PROMIS Global Health will be administered to all patients while the PROMIS Physical Function - Mobility short form will be administered to those with an implant used in a lower extremity and the PROMIS Physical Function - Upper Extremity short form will be administered to those with an implant used in an upper extremity.

    Time frame: 2 years post implant insertion

07

Study locations

1 of 1 sites recruiting
  • BC Children's Hospital
    Vancouver, British Columbia V6H 3N1, Canada
    Recruiting
    • Emily Schaeffer, PhD · Contactemily.schaeffer@cw.bc.ca · 604-875-2359
    • Anthony Cooper, FRCSC · Principal investigator
    • Kishore Mulpuri, FRCSC · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2028, 83 months after the start.

Of 66 non-industry observational studies under Fractures, Bone, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 88. This study's planned 83 months is above that.

Counting every sponsor, half of 86 studies reached it within 46 months; a quarter within 20 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2021
First posted
May 5, 2022
StartActual
Jan 6, 2022
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05361980
Collaborators
OrthoPediatrics
Responsible party
Kishore Mulpuri (Professor, University of British Columbia) — Principal investigator
First posted
May 5, 2022
Start date
Jan 6, 2022
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Bryn Zomar, PhD
Contact
bryn.zomar@cw.bc.ca
604-875-2359
Harpreet Chhina, PhD
Contact
hchhina@cw.bc.ca
604-875-2000 ext. 6008
Bryn Zomar, PhD
study director · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion